40 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
1
Drug discovery strategies to outer membrane targets in Gram-negative pathogens.
AstraZeneca
27
Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
Pfizer
5
Design, Synthesis, and Activity Evaluation of Novel Bifenamide Dual-Target Antibacterial Inhibitors and Carrier Based on Infectious Microenvironment.
Liaocheng University
18
Research progress of LpxC inhibitor on Gram-negative bacteria.
Minzu University of China
28
Development of Fragment-Based Inhibitors of the Bacterial Deacetylase LpxC with Low Nanomolar Activity.
Universitat Hamburg
1
Oxazolidinone: A promising scaffold for the development of antibacterial drugs.
Children's Hospital Affiliated to Zhengzhou University
15
Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
Sichuan University
18
Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.
Duke University
27
N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Entasis Therapeutics
64
Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC.
Chiron
41
Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
Taisho Pharmaceutical
16
Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline.
Novartis Institutes For Biomedical Research
26
Carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis.
Merck Research Laboratories
18
Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents.
Kyorin Pharmaceutical
15
LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents.
Kyorin Pharmaceutical
17
Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Westf£Lischen Wilhelms-Universit£T M£Nster
4
Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.
Duke University
50
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
Pfizer
30
Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
Pfizer
46
Design and synthesis of potent Gram-negative specific LpxC inhibitors.
Merck Research Laboratories
2
Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold.
Jilin University
3
Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding.
Duke University Medical Center
19
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Novartis Institutes For Biomedical Research
2
Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors
Accutar Biotechnology
38
SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
Arbutus Biopharma
15
NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES
Columbia University
22
1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
Novartis
475
Inhibitors of glucocorticoid receptor translocation
Sanford Burnham Prebys Medical Discovery Institute
8
GR196429: a nonindolic agonist at high-affinity melatonin receptors.
Glaxo Wellcome Research and Development